Stockscreener 앱 받기
3.86
0.26%
0.010
시간 외 거래:
3.86
Trisalus Life Sciences Inc 주식(TLSI)의 최신 뉴스
TriSalus publishes preclinical data on drug delivery technology By Investing.com - Investing.com South Africa
TriSalus Life Sciences launches proposed public stock offering - MSN
Should I invest in TriSalus Life Sciences Inc before earningsWall Street Watch & Technical Buy Zone Confirmations - baoquankhu1.vn
TriSalus publishes preclinical data on drug delivery technology - Investing.com
Animal study from TriSalus pumps more immune drug into liver tumors in models - Stock Titan
Update Recap: What is the dividend yield of TriSalus Life Sciences Inc Equity WarrantRate Hike & Precise Entry and Exit Recommendations - baoquankhu1.vn
Published on: 2026-03-18 18:04:21 - baoquankhu1.vn
Analysis Recap: Is TriSalus Life Sciences Inc Equity Warrant benefiting from innovation trends2026 Key Lessons & Capital Efficiency Focused Ideas - baoquankhu1.vn
Canaccord lowers its price target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and maintains a buy rating - MSN
Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating - Insider Monkey
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail
TriSalus Life Sciences Signals Confident Growth Path - TipRanks
11 Fastest Growing Penny Stocks to Buy Right Now - Insider Monkey
TLSIW Stock Price, News & Analysis - Stock Titan
Research Analysts Issue Forecasts for TLSI Q1 Earnings - MarketBeat
Canaccord Genuity Group Has Lowered Expectations for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price - Defense World
TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI) and Shattuck Labs (STTK) - The Globe and Mail
Canaccord Genuity Group Issues Pessimistic Forecast for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price - MarketBeat
Jones Trading reiterates Buy on TriSalus Life Sciences stock after earnings - Investing.com
TriSalus Life Sciences Q4 Earnings Call Highlights - Yahoo Finance
Boston Scientific to buy Penumbra in $14.5 billion deal - AOL.com
TriSalus Life Sciences reaffirms $60M–$62M revenue guidance for 2026 while expanding PEDD portfolio - MSN
Earnings call transcript: TriSalus Life Sciences sees 60% Q4 revenue rise - Investing.com
TriSalus (TLSI) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: TriSalus Life Sciences sees 60% Q4 revenue rise By Investing.com - Investing.com South Africa
TriSalus Life Sciences (NASDAQ:TLSI) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
TriSalus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance - Bluefield Daily Telegraph
Earnings Summary: TriSalus Life Sciences Q4 - Benzinga
Cancer treatment tech firm TriSalus lifts 2025 sales 53%, aims $60-62M in 2026 - Stock Titan
TLSI: Strong revenue growth, expanded product suite, and robust 2026 outlook with $46M new capital - TradingView
TLSI SEC FilingsTriSalus Life Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Exploring TriSalus Life Sciences's Earnings Expectations - Benzinga
Northland Securities Forecasts TLSI FY2025 Earnings - MarketBeat
TriSalus Life Sciences Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
TLSI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
TriSalus to Raise $40M from Stock Sale - National Today
TLSIW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Retail Surge: What are TriSalus Life Sciences Inc Equity Warrants growth levers2025 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
TriSalus Life Sciences (TLSI) to Release Earnings on Thursday - MarketBeat
TLSI PE Ratio & Valuation, Is TLSI Overvalued - Intellectia AI
TriSalus Life Sciences (NASDAQ: TLSI) raises ~$40M in 9.76M-share offering - Stock Titan
Cancer-focused medtech company TriSalus sets March 5 call on 2025 results - Stock Titan
TriSalus prices $40 mln public stock offering - MSN
TLSI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Insider Buying: David Patience Acquires Shares of TriSalus Life Sciences Inc (TLSI) - GuruFocus
TLSI | TriSalus Life Sciences, Inc. Insider Trading - Quiver Quantitative
TLSI | TriSalus Life Sciences, Inc. FinancialsIncome Statement - Quiver Quantitative
TriSalus Life Sciences (TLSI) CFO adds 3,657 shares in open-market buy - Stock Titan
TriSalus director Gary Gordon buys 9,756 shares (TLSI) in open market - Stock Titan
Director William Valle adds 30,487 TriSalus (TLSI) shares - Stock Titan
TriSalus Life Sciences (TLSI) CEO purchases 30,487 common shares - Stock Titan
TriSalus Life Sciences (TLSI) director adds 361,098 shares in open-market buys - Stock Titan
TriSalus Life Sciences announces plans for public offering - Medical Buyer
TriSalus prices $40M public offering at $4.10 per share By Investing.com - Investing.com South Africa
TriSalus Life Sciences Prices Underwritten Public Equity Offering - TipRanks
TriSalus (TLSI) to raise about $40M in underwritten stock sale - Stock Titan
TriSalus to raise $40M from stock sale - BizWest
TriSalus Life Sciences Prices Stock Offering at $4.10 a Share - marketscreener.com
0.85%
1.86%
자본화:
|
볼륨(24시간):